EverPoint Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

EverPoint Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$15.2M	Sell	124,000 -46,000	-27%	-$5.63M	0.28%	97
2016 Q3	$20.8M	Sell	170,000 -5,000	-3%	-$644K	0.37%	69
2016 Q2	$20.4M	Buy	175,000 +100,000	+133%	+$14.2M	0.4%	66
2016 Q1	$10.4M	Buy	+75,000	New	+$11M	0.21%	130
2014 Q4	–	Sell	-30,000	Closed	-$4.97M	–	583
2014 Q3	$4.97M	Sell	30,000 -35,000	-54%	-$5.75M	0.11%	250
2014 Q2	$10.2M	Buy	+65,000	New	+$10.3M	0.21%	142

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

EverPoint Asset Management's ALXN Position: Q4 2016 in Review

EverPoint Asset Management reduced its Alexion Pharmaceuticals (ALXN) stake by 27% in Q4 2016, selling an estimated $5.63M and leaving 124,000 shares worth $15.2M. The position accounts for 0.28% of the portfolio, ranked #97.

EverPoint Asset Management first reported a position in ALXN in Q2 2014 and has held it in 6 quarters since. The position peaked at $20.8M in Q3 2016. 549 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

EverPoint Asset Management held 124,000 shares of Alexion Pharmaceuticals worth $15.2M as of Q4 2016.
EverPoint Asset Management sold 46,000 Alexion Pharmaceuticals shares in Q4 2016, an estimated $5.63M.
Alexion Pharmaceuticals made up 0.28% of EverPoint Asset Management's portfolio in Q4 2016, its #97 holding.
EverPoint Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2014 and has held it in 6 quarters since.
EverPoint Asset Management's Alexion Pharmaceuticals position peaked at $20.8M in Q3 2016.
549 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.